Enterprise Value
470.3M
Cash
259.8M
Avg Qtr Burn
-38.23M
Short % of Float
22.73%
Insider Ownership
1.39%
Institutional Own.
76.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
UDENYCA® ONBODY Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF) Details Arthritis, Psoriasis, Inflammatory disease | Approved Quarterly sales | |
CIMERLI (CHS-201) (Lucentis biosimilar) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Approved Quarterly sales | |
LOQTORZI (Toripalimab) + Chemotherapy Details Nasopharyngeal carcinoma | Approved Quarterly sales | |
UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Toripalimab (anti-PD-1 antibody)(JUPITER-06) + Chemotherapy Details Esophageal Squamous Cell Carcinoma | Phase 3 Update | |
LOQTORZI (Toripalimab) + INO 3112 Details HPV+ oropharyngeal cancer, Cancer | Phase 3 Initiation | |
Casdozokitug (casdozo) w/ atezolizumab & bevacizumab Details Cancer, Hepatocellular carcinoma | Phase 2 Update | |
Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s | Phase 1/2 Data readout | |
Casdozokitug (casdozo) Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
CHS-114 (SRF114) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CHS-131 Details Multiple sclerosis, Non-alcoholic steatohepatitis | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + Chemotherapy Details Cancer, Small cell lung cancer | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGIT Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |